miR-15/16 Restrain Memory T Cell Differentiation, Cell Cycle, and Survival

Publication date: 20 August 2019Source: Cell Reports, Volume 28, Issue 8Author(s): John D. Gagnon, Robin Kageyama, Hesham M. Shehata, Marlys S. Fassett, Darryl J. Mar, Eric J. Wigton, Kristina Johansson, Adam J. Litterman, Pamela Odorizzi, Dimitre Simeonov, Brian J. Laidlaw, Marisella Panduro, Sana Patel, Lukas T. Jeker, Margaret E. Feeney, Michael T. McManus, Alexander Marson, Mehrdad Matloubian, Shomyseh Sanjabi, K. Mark AnselSummaryCoordinate control of T cell proliferation, survival, and differentiation are essential for host protection from pathogens and cancer. Long-lived memory cells, whose precursors are formed during the initial immunological insult, provide protection from future encounters, and their generation is the goal of many vaccination strategies. microRNAs (miRNAs) are key nodes in regulatory networks that shape effective T cell responses through the fine-tuning of thousands of genes. Here, using compound conditional mutant mice to eliminate miR-15/16 family miRNAs in T cells, we show that miR-15/16 restrict T cell cycle, survival, and memory T cell differentiation. High throughput sequencing of RNA isolated by cross-linking immunoprecipitation of AGO2 combined with gene expression analysis in miR-15/16-deficient T cells indicates that these effects are mediated through the direct inhibition of an extensive network of target genes within pathways critical to cell cycle, survival, and memory.Graphical Abstract
Source: Cell Reports - Category: Cytology Source Type: research

Related Links:

Conditions:   Castration-resistant Prostate Cancer;   Metastatic Cancer;   Prostate Cancer Interventions:   Biological: pTVG-HP;   Biological: pTVG-AR;   Drug: Pembrolizumab;   Drug: rhGM-CSF Sponsors:   University of Wisconsin, Madison;   Merck Sharp & Dohme Corp.;   Madison Vaccines, Inc;   Prostate Cancer Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
HPV DNA detection in urine samples of women: "An efficacious and accurate alternative to cervical samples?" Expert Rev Anti Infect Ther. 2019 Sep 13;: Authors: Pattyn J, Van Keer S, Téblick L, Van Damme P, Vorsters A Abstract Cervical cancers are caused by persistent human papillomavirus (HPV) infections [1]. To date, HPV DNA testing using clinician-obtained cervical cells is the reference for identifying cervical infection. However, great interest has been shown for the use of self-sampling methods to detect HPV [2]. One method for self-sampling to be considered is the collection of f...
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
In this study, researchers studied 438,952 participants in the UK Biobank, who had a total of 24,980 major coronary events - defined as the first occurrence of non-fatal heart attack, ischaemic stroke, or death due to coronary heart disease. They used an approach called Mendelian randomisation, which uses naturally occurring genetic differences to randomly divide the participants into groups, mimicking the effects of running a clinical trial. People with genes associated with lower blood pressure, lower LDL cholesterol, and a combination of both were put into different groups, and compared against those without thes...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In conclusion, the agonistic anti-TLR4 mAb induces potent CD8 T-cell-dependent antitumour immunity and an inflammatory response of lesser magnitude than does LPS. The agonistic anti-TLR4 mAb has potential as an adjuvant for use in vaccines against cancer. PMID: 31515801 [PubMed - in process]
Source: Immunology - Category: Allergy & Immunology Authors: Tags: Immunology Source Type: research
This report presents surveillance data for HPV-associated cancers in the US, estimating which of these were attributable to the types targeted by the 9-valent HPV vaccine.Morbidity &Mortality Weekly Report
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Public Health & Prevention Journal Article Source Type: news
Condition:   Cancer Intervention:   Biological: tumor neoantigen Sponsors:   Henan Cancer Hospital;   shanghai neoimmune pharmaceutical technology compony Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This article is protected by copyright. All rights reserved.
Source: Biotechnology Progress - Category: Biotechnology Authors: Tags: RESEARCH ARTICLE Source Type: research
Authors: Okunade KS Abstract Cervical cancer is by far the most common HPV-related disease. About 99.7% of cervical cancer cases are caused by persistent genital high-risk human papillomavirus (HPV) infection. Worldwide, cervical cancer is one of the most common cancers in women with an estimated 528,000 new cases reported in 2012. Most HPV infections clear spontaneously but persistent infection with the oncogenic or high-risk types may cause cancer of the oropharynx and anogenital regions. The virus usually infects the mucocutaneous epithelium and produces viral particles in matured epithelial cells and then cause...
Source: Journal of Obstetrics and Gynaecology - Category: OBGYN Tags: J Obstet Gynaecol Source Type: research
Data from a new study show the importance of taking preventative measures against contracting human papillomavirus, including urging patients to get the HPV vaccine.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of cancer related death in men in Western countries. The standard therapy for metastatic PCa is androgen suppression therapy (AST). Men undergoing AST eventually develop metastatic castration-resistant prostate cancer (mCRPC), of which there are limited treatment options available. Immunotherapy has presented substantial benefits for many types of cancer, but only a marginal benefit for mCRPC, at least in part, due to the immunosuppressive tumor microenvironment (TME). Current clinical trials are investigating monotherapies or combination ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Cytology | Genetics | Vaccines